Aurobindo is lined up to copy 3 of the blockbuster drugs on this tracker, which earned $24.4B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Aurobindo's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved Sep 2026 | $7.7B |
| Farxiga | AstraZeneca | Generic | 2026 | Approved Apr 2026 | $8.4B |
| Rinvoq | AbbVie | Generic | 2037 | Settled Sep 2025 | $8.3B |
Company facts: Aurobindo. Each drug page lists sources for these entries. Brand sales show the size of the market, not Aurobindo's share of it.